Benzathine Penicillin G is a long-acting form of penicillin, an antibiotic used to treat various bacterial infections. Companies engaged in pharmaceutical manufacturing may produce Benzathine Penicillin G in various formulations and dosage forms. They ensure adherence to quality standards, good manufacturing practices (GMP), and regulatory requirements.
Latest Benzathine Penicillin G Companies Updates:
Teva Pharmaceuticals (Israel) Launched their MORPHIZE™ Extended Release (XR) Injectable in the US, offering a long-acting BPG injection with potentially reduced dosing frequency.
Grünenthal GmbH (Germany) Introduced their MORPIRIN® oral morphine tablets with enhanced tamper-resistant features to address opioid diversion concerns.
World Health Organization (WHO) Continued advocating for improved access to BPG through their "Left Behind in Pain" campaign and collaborations with governments and healthcare organizations.
Pfizer (US) The sole supplier of BPG in many countries, including the US, announced a shortage in July 2023 due to increased demand for syphilis treatment. They currently estimate recovery by April 2024.
WHO and other organizations Raised concerns about the shortage's impact on access to essential syphilis treatment, particularly in low- and middle-income countries. They are advocating for alternative treatment options and long-term solutions to ensure consistent BPG availability.
List of Benzathine Penicillin G Key companies in the market
Benzathine Penicillin G Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)